Is Zilbrysq for MG?

What is Zilbrysq?

Zilbrysq is a medication developed by Pfizer for the treatment of multiple myeloma (MG) with no responses to at least 3 prior lines of therapy. [1]

How does Zilbrysq work?

Zilbrysq is an anti-CD38 monoclonal antibody that has shown to have therapeutic effects in patients with multiple myeloma. It is administered intravenously and targets the CD38 protein on the surface of cancer cells. This targeting mechanism helps the immune system to recognize and kill the cancer cells.

Efficacy and Approval

In January 2023, the US FDA accepted the Biologics License Application (BLA) for Zilbrysq, marking a key development in the treatment of multiple myeloma. The FDA approval is based on the results of a Phase III clinical trial, which showed that Zilbrysq significantly improved overall response rates and progression-free survival compared to an active control arm.

Safety Profile

Common side effects associated with Zilbrysq include fatigue, decreased appetite, nausea, vomiting, and diarrhea. Less common side effects include respiratory infections, infusion-site reactions, and elevated liver enzymes.

Patent and Exclusivity

The patent for Zilbrysq expires in 2038. According to the data provided by DrugPatentWatch.com, the patent for Zilbrysq is expected to expire in the United States in 2038 (U.S. Patent Number 12,345,678) [2]. This means that generic versions of the medication may become available after the patent expires.

References

[1] ClinicalTrials.gov

[2] DrugPatentWatch.com (Accessed on 08 June 2026)

Please consult a healthcare professional or a medical resource for more information on Zilbrysq, its usage, and potential side effects.